Harvard Bioscience (FRA:HBI0) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:HBI0 Harvard Bioscience Inc FRA:HBI0
53 GF Score
Price €4.08
GF Value €6.70
! 9 Warning Signs
View Full Analysis

What is Harvard Bioscience Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Harvard Bioscience Quality Rank Related Terms

FRA:HBI0
53GF Score
Harvard Bioscience Inc FRA:HBI0
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?

Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued. The current stock price of €4.08 is trading 39.1% below its estimated GF Value™ of €6.70.

Key valuation signals for FRA:HBI0:

  • Quality Rank:
  • GF Value™: €6.70 vs. price of €4.08 (39.1% below fair value)
  • GF Score™: 53/100 with 9 warning signs

No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harvard Bioscience Business Description

Other Exchanges HBIO:USA
Address 84 October Hill Road, Suite 10, Holliston, MA, USA, 01746
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
53GF Score

Get the complete analysis for FRA:HBI0

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price
€6.70
GF Value